摘要
探讨了阿托伐他汀治疗心肌梗死后无症状心衰患者的临床价值。选取泾川县人民医院2021年1月—2022年1月收治的90例心肌梗死后无症状心衰患者作为研究对象,将所有研究对象均分为实验组(45例)和参照组(45例)。参照组接受常规治疗,实验组在参照组的基础上添加阿托伐他汀联合治疗,分析两组患者治疗后的临床疗效、心室功能指标、血浆NT-proBNP水平、生活质量以及不良反应发生率。研究发现,心肌梗死后无症状心力衰竭患者经阿托伐他汀治疗后,疗效显著,心肌功能改善明显,远期预后良好,值得临床推广应用。
To investigate the clinical value of atorvastatin in the treatment of asymptomatic heart failure patients after myocardial infarction.Ninety patients with asymptomatic heart failure after myocardial infarction admitted to Jingchuan People’s Hospital from January 2021 to January 2022 were selected as research objects,and all the research objects were divided into experimental group(45 cases)and reference group(45 cases).The reference group received routine treatment,and the experimental group added atorvastatin combined treatment on the basis of the reference group.The clinical effcacy,ventricular function indicators,plasma NT proBNP level,quality of life and adverse reaction rate of the two groups of patients after treatment were analyzed.The study found that after treatment with atorvastatin,patients with asymptomatic heart failure after myocardial infarction had significant curative effect,significantly improved myocardial function,and had a good long-term prognosis,which was worthy of clinical application.
作者
种博琴
ZHONG Boqin(Jingchuan People’s Hospital,Pingliang,Gansu 744300)
出处
《科技与健康》
2022年第5期64-66,共3页
Technology and Health
关键词
阿托伐他汀
心肌梗死
无症状心衰
价值分析
atorvastatin
miocardial infarction
silent heart failure
value analysis
